Analysts Conflictied on These Healthcare Names: BioMarin (NASDAQ: BMRN) and Accuray Inc (NASDAQ: ARAY)

By Jason Carr

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BioMarin (NASDAQ: BMRN) and Accuray Inc (NASDAQ: ARAY).

BioMarin (NASDAQ: BMRN)

J.P. Morgan analyst Cory Kasimov maintained a Buy rating on BioMarin (NASDAQ: BMRN) on October 27 and set a price target of $127. The company’s shares closed last Friday at $81.13.

According to TipRanks.com, Kasimov is ranked 0 out of 5 stars with an average return of -15.5% and a 24.4% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals Inc, Karyopharm Therapeutics, and ACADIA Pharmaceuticals.

Currently, the analyst consensus on BioMarin is Strong Buy and the average price target is $118.40, representing a 45.9% upside.

In a report issued on October 12, Leerink Swann also reiterated a Buy rating on the stock with a $127 price target.
Accuray Inc (NASDAQ: ARAY)

BTIG analyst Sean Lavin maintained a Hold rating on Accuray Inc (NASDAQ: ARAY) on October 27. The company’s shares closed last Friday at $5, close to its 52-week low of $4.75.

According to TipRanks.com, Lavin is a top 100 analyst with an average return of 12.5% and a 63.9% success rate. Lavin covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Trivascular Technologies, and Boston Scientific Corp.

Accuray Inc has an analyst consensus of Moderate Buy, with a price target consensus of $10.